Paula G. O’Connor, M.D., has served as Chief Medical Officer of Nurix since May 2024. Dr. O’Connor served as Executive Vice President and Head of Clinical Development from February 2024 through April 2024, and as the company’s Senior Vice President of Clinical Development from September 2022 through January 2024. Dr. O’Connor is trained as a hematologist-oncologist with more than 15 years of drug development expertise. Prior to joining Nurix, Dr. O’Connor held senior level positions in Clinical Development and Medical Affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech. Dr. O’Connor completed her fellowships in Hematology, Oncology, and AIDS Oncology at the combined programs of the Massachusetts General, Brigham and Women’s, and Dana Farber Cancer Institute. She holds a B.A. in Psychology-Biology from Yale University and an M.D. from Stanford University.
'